Invivyd Reports Second Quarter 2026 Financial Results and Recent
Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollme
How this was made
The 30-second read
Why it matters
Traders should focus on (1) the updated cash runway and (2) the stated schedule for VYD2311 pivotal top-line data (late Q3 2026) while also weighing the regulatory overhang from the EUA termination advanced notice for PEMGARDA and the company’s FDA dialogue on next steps.
Market read
A primary filing that combines a modestly positive commercial datapoint (PEMGARDA revenue growth) with a meaningful regulatory risk (EUA termination notice) and a concrete clinical catalyst window (VYD2311 top-line late Q3 2026).
What to watch
R&D expense jumped to $29.4M from $9.6M YoY, which could pressure valuation if pivotal timelines slip or if FDA next steps for PEMGARDA reduce monetization options.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and clinical/program updates for Invivyd’s pemivibart (PEMGARDA) and VYD2311 (DECLARATION and LIBERTY) plus other pipeline items.
Ticker impact
Invivyd reported Q2 2026 PEMGARDA net product revenue of $14.3M (+21% YoY) and disclosed cash of $160.1M plus VYD2311 top-line timing into late Q3 2026.
Moderate two-sided reaction risk: upside from growth and clearer VYD2311 timelines, downside from PEMGARDA EUA termination and higher R&D burn.
The filing is a primary disclosure (8-K with results and program updates). It includes both positive commercial growth and negative regulatory overhang (EUA termination notice), plus a concrete schedule for pivotal readouts.
Market effects
Reinforces ongoing investor focus on COVID-era monoclonal antibody economics, regulatory pathways, and pivot timelines toward next-gen programs.
Limited, company-specific biotech update with no stated regional policy or procurement linkage.
Primarily US regulatory and clinical-trial driven; global revenue implications depend on any post-EUA commercialization strategy.
Counterpoint
PEMGARDA growth may be less durable given the disclosed EUA termination notice, so the market may discount near-term revenue momentum.
Key entities
- companyInvivyd, Inc.
Nasdaq-listed biotech reporting Q2 2026 results, cash position, and pivotal trial timelines for VYD2311.
- productPEMGARDA (pemivibart)
Commercial monoclonal antibody; company reported Q2 net product revenue and disclosed EUA termination advanced notice.
- programVYD2311
Monoclonal antibody prophylaxis program; pivotal DECLARATION and Phase 3 LIBERTY trials with top-line timing into late Q3 2026.
- regulatorFDA
Company is in dialogue on appropriate next steps following EUA termination advanced notice for PEMGARDA.
